TL;DR
Researchers have engineered a thermostable CRISPR-Cas13 enzyme (TccCas13a) that functions optimally at higher temperatures, enabling a robust, one-pot diagnostic assay (OPTIMA-dx) for SARS-CoV-2. This assay is sensitive, specific, and compatible with rapid sample processing, making it suitable for point-of-care applications and even multiplexed detection.
What Problem Does This Paper Address?
Current CRISPR-Cas13 diagnostic systems, while powerful for nucleic acid detection, typically operate at mesophilic temperatures (~37°C). This limitation creates a mismatch with isothermal amplification methods like RT-LAMP, which require higher temperatures (55-65°C) for optimal performance. This necessitates multi-step, two-pot assays, increasing the risk of contamination and complicating point-of-care (POC) implementation. The paper addresses this by identifying and characterizing a thermostable Cas13 ortholog that can function across a broad temperature range, bridging the gap between amplification and detection for a streamlined, one-pot diagnostic.
Methods
The core of this work involves the identification and characterization of a novel thermostable Cas13 enzyme, TccCas13a, from the thermophilic bacterium Thermoclostridium caenicola. Key methods include:
- Phylogenetic Analysis: To identify potential thermophilic Cas13 candidates.
- Protein Expression and Purification: Standard recombinant protein production in E. coli.
- Differential Scanning Fluorimetry (DSF): To assess protein melting points and thermostability.
- SDS-PAGE: To evaluate protein stability under various temperature conditions.
- In Vitro Catalytic Assays: To measure both cis (self-cleavage) and trans (collateral) RNase activities of TccCas13a and a related thermophilic ortholog, HheCas13a, across a range of temperatures.
- CRISPR-Cas13 Sequence Requirement Studies: Investigating the impact of crRNA spacer length and mismatches on TccCas13a activity.
- Pre-crRNA Processing Assays: To determine if TccCas13a, unlike some mesophilic Cas13s, can process its own precursor RNA.
- Enzyme Kinetics: Michaelis-Menten analysis to quantify the catalytic efficiency of TccCas13a.
- One-Pot RT-LAMP-Cas13 Assay Development (OPTIMA-dx): Coupling RT-LAMP for RNA amplification with TccCas13a-based detection in a single tube and at a single temperature (56°C). This involved designing primers with T7 promoter sequences for in vitro transcription of LAMP products.
- Multiplexed Detection: Combining TccCas13a with a thermostable Cas12b enzyme (AapCas12b) to detect multiple targets (SARS-CoV-2 and RNase P) simultaneously using different fluorescent reporters.
- Mobile Application Development: Creating a deep learning-based smartphone app for automated data collection and interpretation of OPTIMA-dx results.
- Clinical Validation: Testing the assay on patient samples and comparing results with qRT-PCR.
- Sample Preparation Optimization: Developing a rapid, extraction-free protocol for sample lysis and concentration.
Datasets
- Synthetic SARS-CoV-2 Genome: Used for determining the limit of detection (LoD) of the OPTIMA-dx assay.
- Clinical Samples:
- 73 qRT-PCR-positive and 27 qRT-PCR-negative samples from patients with COVID-19 were used for clinical validation of OPTIMA-dx.
- 45 randomized samples (40 positive, 5 negative) were used for further validation.
- 16 oropharyngeal swabs from patients with COVID-19 and 2 negative swabs were used for validating multiplexed detection with the quick extraction method.
- Samples spiked with noninfectious SARS-CoV-2 virus particles were used to test the extraction protocol.
- Other Human Viruses: SARS-CoV-1, MERS-CoV, H1N1, HCoV-OC43, HCoV-229E, and HCoV-NL63 were used to assess the specificity of OPTIMA-dx.
- HCV and TYLCV: In vitro-transcribed RNAs of two common HCV genotypes and TYLCV ssDNA virus were used to demonstrate the versatility of OPTIMA-dx for other pathogens.
No new benchmarks were explicitly introduced, but the study validates OPTIMA-dx against the established gold standard, qRT-PCR.
Key Insights and Ideas
- Thermostable Cas13 is a Game Changer for One-Pot Diagnostics: The identification of TccCas13a, which functions effectively at temperatures compatible with RT-LAMP, is a critical step towards truly integrated, single-tube diagnostic assays. This overcomes a major hurdle in current CRISPR-based diagnostics.
- TccCas13a's Unique Properties: TccCas13a exhibits robust cis and trans activity over a broad temperature range (37-70°C) and, interestingly, appears to be defective in precrRNA processing, similar to its close thermophilic relative HheCas13a. This suggests a potential link between thermostability and the lack of precrRNA processing.
- OPTIMA-dx: A Streamlined Diagnostic: The development of OPTIMA-dx demonstrates the power of combining thermostable Cas13 with RT-LAMP for a rapid, sensitive, and specific one-pot assay for SARS-CoV-2. The assay's compatibility with simple extraction methods and visual readout further enhances its POC potential.
- Multiplexing is Achievable: The successful integration of TccCas13a with a thermostable Cas12b enzyme (AapCas12b) for multiplexed detection highlights the potential for simultaneous detection of multiple targets, significantly increasing diagnostic throughput and utility.
- Smartphone Integration for Accessibility: The development of a mobile app for data interpretation and sharing democratizes access to diagnostic results, especially in resource-limited settings.
Key Results
- TccCas13a Activity: TccCas13a exhibits robust cis and trans catalytic activities across a broad temperature range of 37 to 70°C.
- OPTIMA-dx Sensitivity: The assay achieved a limit of detection (LoD) of 10 copies/µL for synthetic SARS-CoV-2 RNA.
- OPTIMA-dx Specificity: OPTIMA-dx showed no cross-reactivity with other tested human viruses.
- Clinical Validation: OPTIMA-dx demonstrated 94.5% sensitivity and 100% specificity when tested on clinical samples, with high concordance to qRT-PCR. The assay could detect samples with Ct values up to 34.
- Multiplexed Detection: The multiplexed OPTIMA-dx assay successfully detected both SARS-CoV-2 and the RNase P internal control in clinical samples.
- Rapid Detection: The OPTIMA-dx assay provided results within 45-60 minutes.
- Extraction-Free Protocol: A rapid, extraction-free sample processing method was developed, compatible with OPTIMA-dx.
Limitations and Future Work
- Pre-crRNA Processing Defect: The inability of TccCas13a and HheCas13a to process precrRNAs is noted as a unique characteristic, potentially linked to their thermostability. Further structural studies are suggested to elucidate this mechanism.
- HheCas13a One-Pot Performance: While HheCas13a showed good performance in two-pot assays, its one-pot performance was not significant. Future work could focus on optimizing HheCas13a for one-pot applications.
- Freeze-Drying Optimization: While reagents were successfully lyophilized, further optimization is needed to enhance reaction speed and performance after freeze-drying.
- Simple Extraction for POC: The authors suggest that future work could focus on developing even simpler extraction methods that integrate lysis and detection into a single step.
- Broader Applications: The thermostable Cas13 enzymes are envisioned for applications beyond diagnostics, including RNA knockdown, editing, imaging, and virus interference, particularly in industrially relevant thermophiles.
- Multiplexed Visual Readout: Future work will include developing a visual readout for multiplexed detection reactions for simpler POC applications.
Summary updated